Anuj Chawla, MD
Ophthalmology · Bakersfield, CANPI 1083841027
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 42 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by Alimera Sciences, Inc. at 52.8% of the total. Reporting peaked in 2019 at $464 and has fallen 93.0% since, to $33 in 2025. That places this record below the midpoint for ophthalmology clinicians in CA, where the typical reported total is $1,218.
Across 42 payments — averaging $29.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alimera Sciences, Inc.$655
- Genentech USA, Inc.$224
- Novartis$179
- Coherus Oncology, Inc.$71
- Mallinckrodt Hospital Products Inc.$44
- Vyera Pharmaceuticals, LLC$25
- plus $44 from 2 others
What the payments were for
- Food & beverage$1,240100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alimera Sciences, Inc. | 20 | $655 |
| Genentech USA, Inc. | 9 | $224 |
| Novartis | 5 | $179 |
| Coherus Oncology, Inc. | 2 | $71 |
| Mallinckrodt Hospital Products Inc. | 2 | $44 |
| Vyera Pharmaceuticals, LLC | 2 | $25 |
| Tearlab Corp | 1 | $24 |
| AbbVie | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Iluvien$193
How this compares
$1,240 in reported general payments places this provider in the 50th percentile of 2,513 ophthalmology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 70 | $2,775 |
| Latanoprost | 142 | $1,027 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 63 | $761 |
| Brimonidine Tartrate | 55 | $493 |
| Atropine Sulfate | 19 | $453 |
| Polymyxin B Sul-TrimethoprimPolymyxin B Sulf/Trimethoprim | 19 | $136 |
| Timolol Maleate | 11 | $54 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Bakersfield
- Daniel ChangBakersfield$820K
- Daniel SchwartzSan Francisco$8M
- Michael BerlinWest Hollywood$5.7M
- Gilbert KlimanMenlo Park$1.5M
- Kuldev SinghStanford$1.5M
- Raymond DouglasBeverly Hills$1.3M
- John AffeldtLoma Linda$1.1M
- Srinivas SaddaPasadena$1M
- Sheri RowenNewport Beach$1M
- Savak TeymoorianLaguna Hills$955K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.